Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Graphite Bio, Inc.

Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform takes CRISPR beyond cutting and harnesses the power of high-efficiency precision DNA repair, also known as homology-directed repair (HDR), to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. Additionally, the company is advancing the development of novel conditioning regimens to help bring curative therapies to more patients. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

See our Community Guidelines at bit.ly/3c5Pztz. 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables		630K -	2.45M 289.37%	2.61M 6.32%	250K 90.41%
accumulated other comprehensive income loss			-401.99M -	-1.05M 99.74%
cash and cash equivalents	6K -	19.78M 329,600%	376.98M 1,805.65%	47.73M 87.34%	185.86M 289.40%
cash and short term investments	6K -	19.78M 329,600%	376.98M 1,805.65%	268.23M 28.85%	185.86M 30.71%
common stock			1K -	1K 0%	1K 0%
deferred revenue			3.87M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt			5.79M -	1.75M 69.81%	77K 95.60%
long term investments				15.32M -	114K 99.26%
net debt	2.20M -	-19.78M 999.59%	-365.70M 1,748.65%	-41.94M 88.53%	-185.50M 342.34%
net receivables
other assets
other current assets		1.29M -	4.76M 270.14%	7.14M 49.92%	2.16M 69.73%
other current liabilities	19K -	31.42M 165,257.89%	337K 98.93%	6.39M 1,796.14%	4.26M 33.30%
other liabilities					1 -
other non current assets			2.17M -	3.00M 38.48%
other non current liabilities		55.92M -		10.82M -	-1 100.00%
othertotal stockholders equity		5.18M -	525.40M 10,036.99%	539.74M 2.73%	550.63M 2.02%
preferred stock			401.99M -
property plant equipment net		1.46M -	18.08M 1,137.58%	28.21M 56.02%	321K 98.86%
retained earnings	-2.22M -	-70.59M 3,082.64%	-141.35M 100.24%	-242.40M 71.49%	-367.05M 51.42%
short term debt	2.21M -		5.48M -	4.04M 26.21%	285K 92.95%
short term investments				220.50M -
tax assets
tax payables
total assets	6K -	22.56M 375,966.67%	401.99M 1,681.54%	321.90M 19.92%	188.46M 41.46%
total current assets	6K -	21.10M 351,616.67%	381.74M 1,708.92%	275.37M 27.87%	188.02M 31.72%
total current liabilities	2.22M -	32.05M 1,341.01%	12.14M 62.11%	13.04M 7.41%	4.80M 63.22%
total debt	2.21M -		11.28M -	5.79M 48.62%	362K 93.75%
total investments				235.82M -	114K 99.95%
total liabilities	2.22M -	87.97M 3,855.58%	17.94M 79.61%	25.61M 42.78%	4.87M 80.97%
total liabilities and stockholders equity	6K -	22.56M 375,966.67%	401.99M 1,681.54%	321.90M 19.92%	188.46M 41.46%
total non current assets		1.46M -	20.25M 1,286.11%	46.54M 129.80%	435K 99.07%
total non current liabilities		55.92M -	5.79M 89.64%	12.57M 116.91%	77.00K 99.39%
total stockholders equity	-2.22M -	-65.41M 2,848.96%	384.05M 687.16%	296.29M 22.85%	183.58M 38.04%

COM:GRAPHITEBIO

Graphite Bio, Inc.

Last Close

3.27

21/03 20:00

Market Cap

185.19M

Beta: -

Volume Today

299.41K

Avg: -

Preview